GBIM:OTCMKTS
GlobeImmune Inc
US$ 0,00010
0,00%
(0,00) 1D
29 de set., 15:48:52 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para GBIM…
Valor de mercado
580,00
Volume médio
1,74 mil
Volume
0,00
Alto — 52 sem
US$ 0,04
Baixo — 52 sem
US$ 0,00
Ações em circulação
5,75 mi
Nº de funcionários
22
Valor de mercado
580,00
Volume médio
1,74 mil
Volume
0,00
Alto — 52 sem
US$ 0,04
Baixo — 52 sem
US$ 0,00
Ações em circulação
5,75 mi
Nº de funcionários
22
Notícias
De fontes da web e parceiros de notícias
Vietnam.vn
·
há 2 horas
Resumo Rápido 15-10: S&P 500 sofre maior queda desde julho após divulgação de dados de inflação; lucro da PV GAS nos primeiros nove meses do ano quase dobra a meta anual.
Times Brasil | CNBC
·
há 7 horas
S&P 500 recua 1% com inflação acima do esperado e queda de ações ligadas à IA
Perfil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Sobre GlobeImmune Inc
CEO-
Funcionários22
Data de fundação1 de jan. de 1995
SedeLouisville, Colorado, Estados Unidos
Setor-
Siteglobeimmune.com